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Epidemiological studies suggest that individuals with type 2 diabetes (T2D) have a
twofold to fourfold increased risk for developing Alzheimer’s disease (AD), however,
the exact mechanisms linking the two diseases are unknown. In both conditions, the
majority of pathophysiological changes, including glucose and insulin dysregulation,
insulin resistance, and AD-related changes in Aβ and tau, occur decades before the
onset of clinical symptoms and diagnosis. In this study, we investigated the relationship
between metabolic biomarkers associated with T2D and amyloid pathology including
Aβ levels, from cerebrospinal fluid (CSF) and fasting plasma of healthy, pre-diabetic
(PreD), and T2D vervet monkeys (Chlorocebus aethiops sabaeus). Consistent with the
human disease, T2D monkeys have increased plasma and CSF glucose levels as they
transition from normoglycemia to PreD and diabetic states. Although plasma levels of
acylcarnitines and amino acids remained largely unchanged, peripheral hyperglycemia
correlated with decreased CSF acylcarnitines and CSF amino acids, including branched
chain amino acid (BCAA) concentrations, suggesting profound changes in cerebral
metabolism coincident with systemic glucose dysregulation. Moreover, CSF Aβ40 and
CSF Aβ42 levels decreased in T2D monkeys, a phenomenon observed in the human
course of AD which coincides with increased amyloid deposition within the brain. In
agreement with previous studies in mice, CSF Aβ40 and CSF Aβ42 were highly correlated
with CSF glucose levels, suggesting that glucose levels in the brain are associated with
changes in Aβ metabolism. Interestingly, CSF Aβ40 and CSF Aβ42 levels were also highly
correlated with plasma but not CSF lactate levels, suggesting that plasma lactate might
serve as a potential biomarker of disease progression in AD. Moreover, CSF glucose
and plasma lactate levels were correlated with CSF amino acid and acylcarnitine levels,
demonstrating alterations in cerebral metabolism occurring with the onset of T2D.
Together, these data suggest that peripheral metabolic changes associated with the
development of T2D produce alterations in brain metabolism that lead to early changes
in the amyloid cascade, similar to those observed in pre-symptomatic AD.
Keywords: metabolomics, type 2 diabetes, Alzheimer’s disease, amyloid-beta, CSF, amino acids, acylcarnitine,
hyperglycemia
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INTRODUCTION
Rates of type 2 diabetes (T2D) and Alzheimer’s disease
(AD) are reaching epidemic proportions and are expected
to continue to rise over the next several decades (Holtzman
et al., 2011). T2D is a metabolic disorder characterized by
elevated fasting plasma glucose levels, increased insulin levels,
insulin resistance, and beta cell dysfunction with the majority of
changes occurring 5–10 years before clinical diagnosis (American
Diabetes Association, 2010). Similarly, pathological hallmarks of
AD, including the extracellular aggregation of amyloid β (Aβ)
into amyloid plaques and the intracellular accumulation of the
tau protein into neurofibrillary tangles (NFTs), begin decades
before cognitive decline and clinical diagnosis (Hardy and Selkoe,
2002; Bateman et al., 2012; Musiek and Holtzman, 2015).
While both are considered diseases of aging and mechanisms
linking the two conditions remain elusive, epidemiological and
cross-sectional studies suggest that individuals with T2D have
a twofold to fourfold increased risk for developing AD and
dementia and show increased AD pathology (Ott et al., 1999;
Crane et al., 2013; Huang et al., 2014). Preclinical studies in
mouse models of cerebral amyloidosis suggest that systemic
hyperglycemia increases Aβ levels within the hippocampal
interstitial fluid (ISF) by 25%; an effect that is amplified when
plaques are already present in the brain during the hyperglycemia
challenge (Macauley et al., 2015; Stanley et al., 2016). Moreover,
mouse plasma glucose, ISF glucose, and ISF Aβ are highly
correlated, and elevated glucose levels drive Aβ production in
the hippocampus in an activity dependent manner (Macauley
et al., 2015). Conversely, systemic hyperinsulinemia at post-
prandial or supra-physiological levels, only modestly increase
ISF Aβ levels. This suggests that changes in glucose, rather than
insulin, correlate more closely with brain Aβ levels (Stanley et al.,
2016). Although these studies suggest a mechanistic link between
T2D and AD, rodent models of AD do not fully recapitulate the
human course of disease, and it is important to translate these
observations to primates. Similar to humans, many non-human
primate species develop T2D and amyloid pathology with age
(Wagner et al., 2006; Latimer et al., 2019), and thus represent
an important translational tool for examining the metabolic
relationship between the two conditions.
Branched chain amino acids (BCAAs), including leucine,
isoleucine, and valine, are essential amino acids necessary
for protein synthesis, but when found in excess, impact
energy homeostasis (Shimomura and Kitaura, 2018; Hudd
et al., 2019; White and Newgard, 2019). Recent work
demonstrated that elevated dietary BCAA intake is associated
with obesity and insulin resistance in both humans and rodents
(Newgard et al., 2009; Solon-Biet et al., 2019), and plasma
BCAA levels are highly predictive of T2D development in
normoglycemic individuals (Wang et al., 2011). Elevated levels of
circulating BCAAs are associated with suppressed mitochondrial
β-oxidation, reduced glucose tolerance, increased insulin
resistance, and increased de novo lipogenesis, making BCAAs a
potential biomarker of metabolic disease (Newgard et al., 2009;
Weiss and Lustig, 2014). BCAAs are also integral to healthy brain
function, due to their roles in neurotransmitter biosynthesis,
protein synthesis, and energy production. Alterations in BCAA
levels in plasma and CSF have been implicated in AD pathology,
with conflicting evidence on whether they are helpful or
harmful to disease progression (Griffin and Bradshaw, 2017).
Nevertheless, alterations in energy homeostasis and BCAA
catabolism represent one potential link between T2D and AD.
Acylcarnitines are byproducts of mitochondrial fatty acid,
amino acid and glucose catabolism that serve as useful
biomarkers of metabolic changes (Jones et al., 2010). Changes in
the plasma acylcarnitine profile have been observed in obesity,
T2D, and insulin resistance, representing alterations in several
metabolic pathways (Jones et al., 2010; Schooneman et al., 2013).
Moreover, acylcarnitines are key energy substrates in the brain,
especially during fasting conditions when glucose levels are low
(Jones et al., 2010). In AD patients, plasma levels of acylcarnitines
are decreased, suggesting perturbations in energy metabolism
that may be central to AD pathogenesis (Cristofano et al., 2016).
Here, we applied comprehensive metabolic profiling tools
to healthy control (Ctrl), pre-diabetic (PreD), and diabetic
(T2D) monkeys to explore the relationship between T2D and
amyloid pathology. We utilized a cohort of aging vervet monkeys
(Chlorocebus aethiops sabaeus), which develop neuropathological
changes consistent with human AD pathology including
increased amyloid plaque burden, elevated cortical tau levels and
paired helical filament tau immunoreactivity, Aβ-related vascular
impairment, reduced cerebral metabolism, regional atrophy,
decreased CSF Aβ42 and increased CSF tau levels (Kalinin
et al., 2013; Chen et al., 2018; Latimer et al., 2019), to ensure
translational relevance of our findings. We analyzed plasma and
CSF amino acids and acylcarnitine concentrations and explored
how these changes related to CSF Aβ40 and Aβ42 levels, which are
established biomarkers of disease in AD.
MATERIALS AND METHODS
Animals
The monkeys used in this study were sourced from a
multigenerational pedigreed colony of vervet monkeys
(Chlorocebus aethiops sabaeus; age = 16.5–23.5 years old).
Veterinary and research staff categorized the monkeys as either
healthy (Ctrl; n = 4), pre-diabetic (PreD; n = 4), or type-2
diabetic (T2D; n = 5) according to repeated fasting glucose
measurements and American Diabetes Association criteria
(American Diabetes Association, 2010) and were selected to
be matched by age, bodyweight, and adiposity as measured
by waist circumference. PreD and T2D categorization was
only made after ≥2 consecutive fasting glucose values were
≥100 mg/dL or ≥126 mg/dL, respectively. T2D monkeys
were maintained with insulin therapy, and all T2D monkeys
in study had been diagnosed and treated for a minimum of
2 years. Monkeys were fed a commercial laboratory primate
chow diet (Laboratory Diet 5038; LabDiet., St. Louis, MO,
United States), with daily supplemental fresh fruits and
vegetables. This standard laboratory diet is comprised of
13% calories from fat; 69% calories from carbohydrates; and
18% of calories from protein. All samples were collected
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after 16 h fasting and withdrawal from all exogenous insulin.
Cerebrospinal fluid (CSF) was collected via puncture of the
atlanto-occipital space, and plasma samples were collected from
the femoral vein.
All animal procedures were performed on a protocol approved
by the Wake Forest University Institutional Animal Care and Use
Committee according to recommendations in the Guide for Care
and Use of Laboratory Animals (Institute for Laboratory Animal
Research) and in compliance with the USDA animal Welfare
Act and Animal Welfare Regulations (Animal Welfare Act as
Amended; Animal Welfare Regulations).
AD Biomarkers
Aβ40 and Aβ42 levels from CSF samples were assayed using
sandwich ELISAs as previously described (Bero et al., 2011;
Roh et al., 2012). Briefly, Aβ40 and Aβ42 were quantified using
monoclonal capture antibodies (a generous gift from David
Holtzman) targeted against amino acids 45–50 (HJ2) or 37–
42 (HJ7.4), respectively. For detection, both Aβ40 and Aβ42
used a biotinylated monoclonal antibody against the central
domain (HJ5.1B), followed by incubation with streptavidin-
poly-HRP-40. Assays were developed using Super Slow TMB
(Sigma) and the plates read on a Bio-Tek Synergy 2 plate reader
at 650 nm.
Metabolomics, Lipids, Glucose, and
Lactate Measures
Glucose and lactate measurements within the plasma and
CSF were quantified using a YSI 2900 analyzer as previously
described (Macauley et al., 2015). A detailed description
of blood and CSF sample preparation and coefficients
of variation for these assays has been published (Haqq
et al., 2005; Solon-Biet et al., 2019). Insulin was measured
by ELISA (Mercodia, Uppsala, Sweden) in plasma and
CSF samples. Total cholesterol, high density lipoprotein
(HDL) and low-density lipoprotein (LDL) cholesterol, and
triglycerides were measured with kits from Roche Diagnostics
(Indianapolis, IN, United States) and free fatty acids (total)
and ketones (total and 3-hydroxybutyrate) with kits from
Wako (Richmond, VA, United States). ApoB associated
cholesterol was calculated as the total cholesterol minus
HDLC. Plasma and CSF acylcarnitines and amino acids were
analyzed by MS/MS as described previously (Millington et al.,
1990; Chace et al., 1995; An et al., 2004; Wu et al., 2004;
Ferrara et al., 2008).
Data Analysis
Data were analyzed using one-way ANOVA and correlations
were determined by Pearson’s correlation coefficient, r. To
determine the relative relationship between CSF Glucose, CSF
Aβ42, and plasma lactate and CSF analytes, we transformed
each data point to represent its value relative to the control
group mean [% control mean value = 100∗(x/control mean),
where x = any given data point]. Data are represented
as means ± SEM. Tukey’s post hoc tests were used
when appropriate.
RESULTS
Metabolic Profile of Normoglycemic,
Pre-diabetic, and T2D Monkeys
Monkeys were older, ranging from 16 to 23 years (Table 1),
which represents the last 30% of lifespan for this species and
is a typical age range for the onset of metabolic diseases
and neuropathological changes associated with AD (Kalinin
et al., 2013; Chen et al., 2018; Latimer et al., 2019). There
were no differences in body weight or waist circumference
between groups (Table 1). PreD and T2D monkeys had elevated
fasting blood glucose levels compared to normoglycemic controls
[Table 1; p < 0.0001, F(2,9) = 39.17], but there were no
differences in fasting insulin levels (Table 1). While HOMA
scores were elevated in PreD and T2D monkeys, the differences
were not significant (Table 1). Additionally, lipid measures
illustrated higher triglycerides in T2D monkeys compared to
PreD or Ctrl. Together, elevated fasting blood glucose was the
most notable finding delineating the Ctrl, PreD, and T2D cohorts.
Increased CSF Glucose Levels
Correlated With Decreased CSF Aβ40 and
Aβ42 Concentrations in T2D Monkeys
T2D monkeys have elevated plasma glucose [Figure 1A;
p = 0.0036, F(2,10) = 10.39] and CSF glucose concentrations
[Figure 1B; p < 0.0001, F(2,9) = 32.31] compared to
normoglycemic controls, while PreD had intermediate values.
Data analysis revealed that plasma and CSF glucose levels
had a strong positive correlation (Figure 1C; p < 0.0002,
r = 0.8739, R2 = 0.7637), which is consistent with observations
from preclinical rodent models (Macauley et al., 2015). We
also observed that plasma lactate levels were lower in T2D
monkeys [Figure 1D; p = 0.0395, F(2,10) = 4.544], however,
no differences in CSF lactate concentrations were observed
(Figure 1E). We previously demonstrated that hyperglycemic
APP/PS1 mice, a model of cerebral amyloidosis, have elevated
Aβ within the brain’s ISF (Macauley et al., 2015; Stanley et al.,
2016), and non-human primates with T2D have increased Aβ
deposition in several brain regions (Okabayashi et al., 2015).
T2D monkeys have decreased CSF Aβ40 [Figure 1F; p = 0.0280,
F(2,9) = 5.030], and CSF Aβ42 concentrations [Figure 1J;
p = 0.0342, F(2,9) = 5.463]. Interestingly, both CSF Aβ40 and
CSF Aβ42 were highly correlated with CSF glucose (Figure 1G;
p = 0.0400, r = −0.5979, R2 = 0.3575 and Figure 1K; p = 0.0489,
r = −0.5782, R2 = 0.3343, respectively) and plasma lactate
(Figure 1H; p = 0.0027, r = 0.7820, R2 = 0.6115 and Figure 1L
p = 0.0013, r = 0.8133, R2 = 0.6614; respectively) but not
with plasma insulin (Figures 1I,M). CSF insulin levels were
undetectable. Given that decreased CSF Aβ is indicative of
increased plaque formation within the brain (Tapiola et al.,
2009), these data indicate that T2D monkeys display biomarkers
of early amyloid deposition and pre-symptomatic AD (Kalinin
et al., 2013; Chen et al., 2018; Latimer et al., 2019) triggered
by a state of energy dysregulation, which is consistent with
previous work in rodent models (Macauley et al., 2015;
Stanley et al., 2016).
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TABLE 1 | Demographic and metabolic characteristics of monkeys included in study.
Ctrl Mean (SEM) PreD Mean (SEM) T2D Mean (SEM) One-Way ANOVA
Age (years) 20.25 (±1.109) 18.75 (±0.6292) 18.00 (±1.304) p = 0.3800
Body weight (kg) 5.553 (±0.5525) 6.618 (±0.9210) 5.414 (±0.4937) p = 0.4100
Waist circumference (cm) 36.98 (±1.719) 41.94 (±3.861) 38.08 (±3.441) p = 0.5283
Fasting glucose (mg/dL) 67.84 (±5.097) 113.80 (±4.308) 161.10 (±11.05) p < 0.0001
Fasting insulin (µlU/mL) 20.83 (±4.806) 37.43 (±8.854) 26.63 (±8.191) p = 0.3284
HOMA Score (AU) 3.613 (±1.048) 10.61 (±2.721) 10.64 (±3.525) p = 0.1512
TPC (mg/dL) 171.3 (±10.06) 198.9 (±33.75) 164.3 (±9.067) p = 0.4945
Triglyceride (mg/dL) 74.33 (±2.541) 59.75 (±7.417) 103.80 (±16.19) p = 0.0407
HDLC (mg/dL) 60.59 (±4.389) 65.50 (±5.939) 59.83 (±3.657) p = 0.6702
ApoB-associated cholesterol (mg/dL) 110.70 (±6.232) 95.22 (±8.152) 104.40 (±6.809) p = 0.3633
TPC/HDLC 2.845 (±0.093) 2.360 (±0.130) 2.785 (±0.148) p = 0.0646
Ctrl = Control; PreD = Pre-Diabetic; T2D = Type-2 Diabetic; HOMA = Homeostatic model assessment. TPC = Total plasma cholesterol; HDLC = High-density
lipoprotein cholesterol.
FIGURE 1 | Type 2 diabetes (T2D) monkeys have significantly decreased cerebrospinal fluid (CSF) Aβ40 and CSF Aβ42 concentrations, which is correlated with CSF
glucose and plasma lactate concentrations. (A) plasma glucose and (B) CSF glucose concentrations were significantly elevated in T2D monkeys. (C) Plasma and
CSF glucose concentrations were significantly correlated. (D) T2D monkeys had significantly decreased plasma lactate, but not (E) CSF lactate. (F) T2D monkeys
had significantly decreased Aβ40, which was correlated with (G) CSF glucose and (H) plasma lactate, but not (I) plasma insulin concentrations. (J) Similarly, T2D
monkeys had significantly decreased Aβ42 concentrations, which was correlated with (K) CSF glucose and (L) plasma lactate, but not (M) plasma insulin
concentrations.∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; and ∗∗∗∗p < 0.0001; one-way ANOVA with Tukey’s post hoc test. Values represent mean ± SEM; solid lines
represent statistically significant correlations (p < 0.05).
T2D and PreD Monkey Show Decreased
Amino Acid and Acylcarnitines Levels in
the CSF but Not the Plasma
Because plasma amino acid and acylcarnitine levels are linked
to metabolic dysfunction in T2D (Schooneman et al., 2013;
Shin et al., 2014), the levels of amino acids (AA) in both
the plasma and CSF were quantified to further explore the
energy imbalance associated with T2D. In examining the AA
concentrations by their functional groups, PreD and T2D
monkeys had lower concentrations of amino acids in the
CSF. Amino acids were further stratified into branched-chain
AA [BCAAs, Figure 2A; p = 0.0038, F(2,9) = 11.04], total
AA [Figure 2B; p = 0.0081, F(2,9) = 8.638], essential AA
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[Figure 2C; p = 0.0065, F(2,9) = 9.280], aromatic AA [Figure 2D;
p = 0.0046, F(2,9) = 10.36], and basic AA [Figure 2E; p = 0.0087,
F(2,9) = 8.421] (Supplementary Table S1). In the CSF, all AA
groups were lower in T2D, with the exception of acidic AA
where no changes were detected (Figure 2F). No differences
in plasma AA concentrations were detected in any of the
AA categories (Figures 2G–L). Interestingly, when individual
AAs were measured in plasma (Supplementary Table S3 and
Supplementary Figure S2), there was a trend toward an
increase in levels of the BCAAs valine and leucine/isoleucine
(Supplementary Figure S2F; p = 0.0977 and Supplementary
Figure S2M; p = 0.1675, respectively), suggesting peripheral
metabolic perturbations were present, although the differences
in CSF amino acids (Supplementary Figures S1A–O and
Supplementary Table S4), valine and leucine/isoleucine in
particular, were more striking (Supplementary Figure S1F;
p = 0.0219 and Supplementary Figure S1M; p = 0.0524).
Acylcarnitines are derived from the mitochondrial
oxidation of fatty acids, carbohydrates, and amino acids
(Schooneman et al., 2013). Several studies have shown that
T2D patients have elevated plasma acylcarnitine concentrations
compared to healthy controls (Muoio, 2014). Here, T2D
monkeys had lower total acylcarnitine concentrations in
the CSF [Figure 3A; p = 0.0208, F(2,9) = 6.139], but no
differences in plasma total acylcarnitine levels (Figure 3C),
a pattern consistent with the AA data (Supplementary
Table S2). In the CSF, T2D monkeys also had lower short-
chain acylcarnitine concentrations [Figure 3B; p = 0.0245,
F(2,9) = 5.764]. However, due to variability in the control
monkeys, medium- and long-chain acylcarnitine concentrations
were consistently lower in T2D monkeys, but the difference
did not reach significance (Muoio, 2014; Figures 3C,D).
Again, plasma concentrations remained comparable between
groups (Figures 3F–H). Together, this data suggests that fuel
metabolism is altered in the brains of T2D monkeys compared to
normoglycemic controls.
Metabolic Dysregulation in the Brain Is
Associated With Changes in CSF
Glucose, Plasma Glucose, CSF Aβ42, and
Plasma Lactate
Lastly, we investigated the relationship between differences in
CSF amino acids and CSF acylcarnitines as a function of
CSF glucose, CSF Aβ42, and plasma lactate concentrations
(Figure 4) to further elucidate the interaction between early
metabolic changes in T2D with early biomarker alterations
in AD. There was an overall negative relationship between
CSF glucose and Aβ40, Aβ42, total AA, essential AA, BCAA,
aromatic AA, basic AA, short-chain acylcarnitine, and total
acylcarnitine (Figure 4A). Thus, as CSF glucose increases as
observed in PreD and T2D, concentrations of amino acids,
acylcarnitines, and Aβ all decrease in the CSF. Plasma glucose
was correlated with CSF BCAA, total AA, essential AA, aromatic
AA, and basic AA, but not CSF Aβ40, CSF Aβ42, or CSF
acylcarnitines (Figure 4B and Supplementary Table S6). Next,
CSF Aβ42 was correlated with CSF Aβ40 and CSF BCAA
(Figure 4C), reinforcing the relationship between BCAAs
and amyloid pathology. Lastly, plasma lactate concentrations
correlated with CSF Aβ40 and Aβ42, CSF essential AA and BCAA,
and CSF short-chain and total acylcarnitine concentrations
(Figure 4D), demonstrating plasma lactate might be a potential
biomarker for early changes in T2D and pre-symptomatic
AD. Taken together, alterations in cerebral metabolism co-vary
with changes in plasma glucose, plasma lactate, and CSF Aβ42
which highlight the importance of metabolic changes in the
pathogenesis of T2D and AD.
DISCUSSION
In this study, elevated fasting blood glucose levels associated
with the onset of T2D elicit changes in brain metabolism
and correlate with changes in the amyloid cascade, an early
indicator of presymptomatic AD (Crane et al., 2013; Macauley
et al., 2015). Aged monkeys (>19 years) can develop pathology
consistent with human AD including increased amyloid plaque
burden, elevated cortical tau levels and paired helical filament
tau immunoreactivity, Aβ-related vascular damage, reduced
cerebral metabolism, regional atrophy, and alterations in CSF
biomarkers including both Aβ and tau (Kalinin et al., 2013;
Chen et al., 2018; Latimer et al., 2019). Moreover, reductions in
CSF Aβ levels correlate with increased amyloid plaque burden
and insoluble Aβ levels in the cortex, similar to findings from
human studies. In this study, T2D monkeys had lower CSF
Aβ40 and Aβ42 levels, which is indicative of increased amyloid
deposition within the brain (Tapiola et al., 2009). In agreement
with previous rodent studies (Macauley et al., 2015; Stanley
et al., 2016), CSF Aβ40 and Aβ42 were highly correlated with
CSF glucose levels, which suggests that increased glucose may
be driving Aβ production and aggregation in these animals.
Interestingly, CSF Aβ40 and Aβ42 levels also highly correlated
with plasma lactate levels, which is consistent with published
studies that show decreased plasma lactate correlates with AD
severity (Lu et al., 2015; Verri et al., 2018). Moreover, T2D vervet
monkeys had lower CSF acylcarnitine and CSF amino acids,
while plasma levels were largely unchanged, suggesting either
early changes in cerebral metabolism with the onset of T2D or
changes in the transport of certain metabolic fuels to the brain.
Reduced CSF Aβ40 and Aβ42 levels in T2D monkeys correlated
with higher plasma and CSF glucose concentrations, suggesting
increased amyloid plaques are related to glucose dysregulation.
Lastly, we showed that CSF amino acids and acylcarnitines
were negatively correlated with CSF glucose and positively
correlated with CSF Aβ40, CSF Aβ42, and plasma lactate.
Together, these data suggest that peripheral metabolic changes
associated with diabetogenesis co-occur with alterations in brain
metabolism. Moreover, these metabolic changes are associated
with activation of the amyloid cascade typically observed in
humans with pre-symptomatic AD. Future postmortem studies
in T2D monkeys should examine tau hyperphosphorylation,
NFTs, and amyloid plaques in addition to changes in CSF
Aβ levels to further strengthen the connection between T2D
and AD pathology.
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FIGURE 2 | Amino acid(AA) concentrations are decreased in the cerebrospinal fluid (CSF) but not plasma of type 2 diabetes (T2D) monkeys. (A) T2D monkeys had
significantly decreased branch chain amino acids (BCAA), (B) total amino acid concentrations, (C) essential AAs, (D) aromatic AAs, and (E) basic AAs, but not (F)
acidic AAs. (G–L) Conversely, plasma amino acid concentrations were not different between groups. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; and ∗∗∗∗p < 0.0001;
one-way ANOVA with Tukey’s post hoc test. Values represent mean ± SEM.
FIGURE 3 | Acylcarnitine concentrations are decreased in the cerebrospinal fluid (CSF) but not plasma of type 2 diabetes (T2D) monkeys. (A,B) Total and
short-chain acylcarnitine concentrations were significantly decreased in the plasma of T2D and IR monkeys, (C,D), however, medium- and long-chain acylcarnitines
were not significantly different. (E–H) There were no differences in plasma acylcarnitine concentrations between groups.∗p < 0.05; one-way ANOVA with Tukey’s
post hoc test. Values represent mean ± SEM.
Our data further supports existing evidence that chronic
hyperglycemia and metabolic dysfunction are a pathological
link between T2D and AD. In humans, hyperglycemia increases
dementia risk in both patients with and without diabetes, causes
rapid progression from mild cognitive impairment (MCI) to
symptomatic AD, and increases the rate of amyloid accumulation
in the brain (Crane et al., 2013; Morris et al., 2014). Moreover,
hyperglycemia and increased HbA1c levels correlate with
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FIGURE 4 | Metabolic dysregulation is associated with changes in plasma lactate, cerebrospinal fluid (CSF) glucose, and CSF Aβ40 and Aβ42. Here, each data point
has been converted into a value that represents the % of the control group’s mean [value = 100∗(x/control group mean)]. (A) Normalized CSF glucose values were
negatively correlated with several normalized CSF analytes. (B) Normalized plasma glucose were negatively correlated with normalized CSF amino acids, but not
normalized CSF Aβ40, Aβ42, or acylcarnitines. (C) Normalized CSF Aβ42 was correlated with normalized CSF analytes. (D) Normalized plasma lactate values were
positively correlated with several normalized CSF analytes. (E) Thus, the model we propose here is that type 2 diabetes (T2D) moves the brain into a state of
hypermetabolic overconsumption wherein the brain consumes increased energy, leading to lower concentrations of Aβ42 in the CSF, which is indicative of increased
Aβ aggregation. Lines represent non-linear regression best fit curve; solid lines indicate statistical significance.
memory impairment, decreased functional connectivity, and
increased neuronal loss, independent of T2D or AD diagnosis
(Zheng et al., 2018). Data from T2D monkeys illustrates the same
phenomenon; elevated blood glucose levels increase CSF glucose
which correlates with changes in CSF Aβ levels, presumably due
to the sequestration of Aβ into amyloid plaques in the brain
(Bateman et al., 2006). Our findings in the T2D monkeys also
uncovered an interesting relationship between glucose, lactate,
and Aβ which supports previous findings from rodent studies.
Preclinical studies in mouse models of cerebral amyloidosis
demonstrate that synaptic release of Aβ occurs in an activity
dependent manner, where high levels of synaptic activity increase
Aβ secretion (Cirrito et al., 2003; Cirrito et al., 2005; Bateman
et al., 2006; Cirrito et al., 2008). Increased synaptic activity not
only drives ISF Aβ release but also the release of lactate into
the extracellular space (Bero et al., 2011). According to the
astrocyte neuron lactate shuttle, lactate is a preferred energy
source for neurons to sustain excitatory neurotransmission and
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levels of ISF lactate correlate with neuronal activity. Our previous
work demonstrated that hyperglycemia not only increases ISF
glucose and ISF Aβ but also ISF lactate, illustrating that
increased metabolic activity is linked with increased synaptic
activity and Aβ release. Since a direct measure of lactate
production in the brain of T2D monkeys was unattainable in
this study, we explored how plasma and CSF levels changed
with peripheral hyperglycemia. Interestingly, plasma lactate, but
not CSF lactate, correlated with changes in CSF glucose and
Aβ. In accordance with our previous work, we hypothesize that
increased glucose metabolism is increasing neuronal activity
within the brain and driving both the production of Aβ and
the consumption of pyruvate and lactate as fuel. Although the
changes in plasma lactate levels could be due to alterations
in peripheral metabolism in the T2D monkeys, we propose
a different mechanism where increased lactate consumption
in the brain signifies a hyperactive and hypermetabolic brain
state present in both T2D and AD (Figure 4E). Since the
concentration gradient for lactate favors transport from brain
to blood (Raichle et al., 1970), decreased plasma lactate levels
could reflect increased neuronal activity, lactate consumption,
and Aβ production in the brain, which also makes plasma
lactate levels a potential serum biomarker for AD, T2D, or
both. In humans, a small cohort study established that serum
lactate levels decreased in symptomatic AD, yet the authors
attributed this finding to alterations in muscle metabolism, not
brain (Verri et al., 2018). Because the majority of the changes
in lactate were found in the plasma and not the CSF, an
alternative hypothesis is that T2D suppresses neuronal activity
leading to the decreased CSF Aβ40 and Aβ42 concentrations.
However, this is unlikely given that CSF Aβ was significantly
decreased in T2D monkeys relative to healthy controls in spite
of the unaltered CSF lactate concentrations. Thus, additional
studies are needed in order to elucidate the role of plasma
lactate in T2D and AD.
In the current study, we demonstrated that T2D monkeys
have lower CSF acylcarnitine and amino acid concentrations
(Figures 2, 3). Several studies demonstrated that circulating
levels of amino acids are positively correlated with obesity,
insulin resistance, metabolic dysfunction, and T2D in humans
and rodents (Newgard et al., 2009; Wang et al., 2011; Solon-
Biet et al., 2019). Although our data demonstrates a trend
toward an increase in the BCAAs valine and isoleucine/leucine,
no differences in plasma amino acid concentrations were
detected in PreD or T2D monkeys. This may be explained
by the fact that the T2D monkeys in this study were fed
a well-controlled, balanced diet that did not replicate the
traditional nutritional overconsumption seen humans with
metabolic syndrome and T2D. Although the T2D monkeys were
hyperglycemic, their insulin levels were unchanged, suggesting
that the hyperglycemia may arise via a mechanism independent
of insulin resistance. Studies reporting elevated plasma BCAAs
in humans have involved obese and insulin resistant subjects
(Newgard et al., 2009; Solon-Biet et al., 2019). Therefore, future
studies should explore the relationship between plasma and CSF
amino acid levels in a non-human primate model of dietary
induced metabolic syndrome and T2D.
Another explanation for the difference in CSF AA levels
could be that the T2D brain is overconsuming amino acids
as fuel or rapidly increasing protein synthesis. While glucose
is the primary source of energy for the brain, the brain can
readily use fatty-acids as energy substrates; however, this typically
occurs with decreased glucose availability, such as fasting or
starvation (Costa et al., 1999). This could lead the brain to a
state of hypermetabolic overconsumption if both glucose and
fatty acid metabolism were upregulated. Furthermore, because
many of the amino acids consumed by the brain are necessary
for neurotransmitter biosynthesis or neurotransmission itself
(Sperringer et al., 2017), we propose that increased amino acid
consumption increases both synaptic activity and metabolic
activity, leading to elevated Aβ production, oxidative stress,
and Aβ aggregation. Our current data cannot discern if the
decrease in amino acids and acylcarnitines in the CSF is
due to increased oxidation, or by another means, such as
altered amino acid transport (Supplementary Figure S3 and
Supplementary Table S5), therefore additional studies will need
to further elucidate mechanisms underlying the changes in
CSF metabolites.
CONCLUSION
The data presented here show that in the progression from
healthy to PreD to T2D, the brain moves into a state of
altered metabolism that results in an increase in glucose and
lowering of amino acids and acylcarnitines in the CNS. Increased
cerebral metabolism drives Aβ production and accelerates Aβ
aggregation, which reciprocally escalates the disease cascades
in T2D and AD. These findings shed further light on the
metabolic link between T2D and amyloid pathology and how
T2D progression could lead to AD-related pathology and
cognitive decline.
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FIGURE S1 | T2D monkeys had significantly decreased levels of several essential,
branched chain, and aromatic amino acids in the CSF. (A–E) T2D and PreD
monkeys had significantly decreased glycine, proline, methionine,
aspartate/asparagine, and tyrosine. (F–J) T2D monkeys had significantly
decreased valine, phenylalanine, ornithine, citrulline, and arginine. (K–O) There
were no differences in alanine, serine, leucine/isoleucine, histidine, or
glutamine/glutamic acid between groups.
FIGURE S2 | There were no differences in amino acid concentrations between
groups in the plasma. (A–O) Plasma amino acid concentrations were similar
between Ctrl, PreD, and T2D monkeys.
FIGURE S3 | Amino acids carried by large neutral amino acid or L-type
transporters, but not A, N, or EAAT transporters, were decreased in the CSF of
T2D monkeys. (A,B) Amino acids (AAs) carried by large neutral amino acid
(LNAA)- or L-type-transporter were decreased in the CSF of T2D monkeys. (C,D)
There were no differences in A-, N-, and EAAT-transporter AA concentrations in
the CSF of PreD and T2D monkeys. (F–J) There were no differences in LNAA-,
L-type-, A-, N-, and EAAT-transported amino acid concentrations in plasma of
PreD or T2D monkeys compared to controls.
TABLE S1 | Descriptive statistics of amino acid data (see Figure 2).
TABLE S2 | Descriptive statistics of acylcarnitine data (see Figure 3).
TABLE S3 | Descriptive statistics of CSF amino acid data (see Supplementary
Figure S1).
TABLE S4 | Descriptive statistics of plasma amino acid data (see Supplementary
Figure S2).
TABLE S5 | Descriptive statistics of amino acid data, grouped by AA transporter
(see Supplementary Figure S3).
TABLE S6 | Descriptive statistics of normalized CSF glucose, plasma glucose,
CSF Aβ42, and plasma lactate with various CSF analytes. See Figure 4.
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